Acetaminophen Caffeine
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Acetaminophen + Caffeine: Drug Repurposing Candidate Assessment
One-Sentence Summary
Acetaminophen + Caffeine is a fixed-dose analgesic combination in which caffeine acts as an adjuvant to enhance the pain-relieving effect of acetaminophen. The TxGNN model did not generate any repurposing predictions for this drug pair in the current pipeline run. This report documents the critical data gaps and outlines the remediation steps required before a full evaluation can be conducted.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no regulatory records retrieved) |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only; no supporting studies |
| US Market Status | Not marketed (0 NDA records on file) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
US Market Information
No US market authorizations were retrieved for the combined entity “ACETAMINOPHEN; CAFFEINE.” The TFDA query returned 0 results (query ID 1, 2026-03-24). Although both active ingredients are individually available over-the-counter in the United States, no NDA record for this fixed-dose combination was found in the current data pull.
Note: The FDA Orange Book lists numerous acetaminophen + caffeine OTC products (e.g., Excedrin Tension Headache). The absence of records here likely reflects a query-string mismatch or scope limitation of the current data source, and should be verified before drawing conclusions about market status.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction pipeline returned no candidate indications for this combination, and all three critical data layers — regulatory records, mechanism of action, and safety warnings — are absent. A meaningful repurposing evaluation cannot be completed without first resolving these gaps.
To proceed, the following is needed:
- Resolve DrugBank ID: The DrugBank query returned 1 result (query ID 3) but no DrugBank ID was captured. Confirm and record the canonical ID(s) for acetaminophen (DB00316) and caffeine (DB00201) individually, then re-run the pipeline at component level.
- Re-run TxGNN at component level: Combination products are better handled as separate ingredient queries. Run predictions for acetaminophen and caffeine independently.
- Retrieve MOA data: Pull mechanism of action from DrugBank API for both components to enable mechanistic plausibility analysis.
- Obtain package insert warnings: Download the FDA label PDF and extract key warnings, contraindications, and drug interactions for safety pre-screening.
- Verify market status: Cross-check the FDA Orange Book for acetaminophen + caffeine combination products to confirm whether OTC approvals exist and should be included.
- Clarify candidate intent: Determine whether the research target is the combination as a unit or one of the individual components; this will determine the correct TxGNN query strategy.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.